GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzymotec Ltd (NAS:ENZY) » Definitions » EV-to-EBITDA

Enzymotec (Enzymotec) EV-to-EBITDA : -83.54 (As of May. 05, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enzymotec EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Enzymotec's enterprise value is $277.62 Mil. Enzymotec's EBITDA for the trailing twelve months (TTM) ended in Sep. 2017 was $-3.32 Mil. Therefore, Enzymotec's EV-to-EBITDA for today is -83.54.

The historical rank and industry rank for Enzymotec's EV-to-EBITDA or its related term are showing as below:

ENZY's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.55
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Enzymotec's stock price is $11.85. Enzymotec's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2017 was $-0.269. Therefore, Enzymotec's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Enzymotec EV-to-EBITDA Historical Data

The historical data trend for Enzymotec's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymotec EV-to-EBITDA Chart

Enzymotec Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EV-to-EBITDA
Get a 7-Day Free Trial - 38.29 13.63 21.33 3,140.83

Enzymotec Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.48 3,140.83 -111.20 -35.82 -69.13

Competitive Comparison of Enzymotec's EV-to-EBITDA

For the Biotechnology subindustry, Enzymotec's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzymotec's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzymotec's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Enzymotec's EV-to-EBITDA falls into.



Enzymotec EV-to-EBITDA Calculation

Enzymotec's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=277.620/-3.323
=-83.54

Enzymotec's current Enterprise Value is $277.62 Mil.
Enzymotec's EBITDA for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzymotec  (NAS:ENZY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Enzymotec's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=11.85/-0.269
=At Loss

Enzymotec's share price for today is $11.85.
Enzymotec's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.269.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Enzymotec EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Enzymotec's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzymotec (Enzymotec) Business Description

Traded in Other Exchanges
N/A
Address
Enzymotec Ltd is nutritional and food ingredients company. It develops and manufactures nutritional ingredients and medical foods based on proprietary technologies. Its product portfolio includes Infat, K-Real, Enzy PS solutions, Vayacog, Vayarin and Vayaroll. The company has Nutrition and Vaya Pharma reportable segments. It derives majority of its revenues from Nutrition segment. The firm mainly operates in America, Europe, Australia, Asia, and Israel.

Enzymotec (Enzymotec) Headlines

From GuruFocus

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon 07-01-2016

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson 12-07-2015

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi 12-20-2016